BioSpace News Archive

Strong growth in net sales to $12.1 million, improved gross margin, and significantly improved marketing efficiency year-over-year.

Nabriva Therapeutics plc announced its financial results for the three and nine months ended September 30, 2019 and recent corporate highlights.

Third Quarter 2019 NUZYRA® (omadacycline) Net Sales increased 82% versus the Prior Quarter to $3.1 Million

Quotient Limited, a commercial-stage diagnostics company, announced the closing of its previously announced underwritten public offering of 13,800,000 ordinary shares at a price to the public of $7.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,800,000 additional ordinary shares.

Adaptive Biotechnologies Corporation reported financial results for the quarter ended September 30, 2019.

Product and product-related services revenue increased by 228% and 125% in the three and nine-month periods, respectively, compared to the prior year periods

Disclosed complement C3 as the target for NGM621, an inhibitory antibody intended to treat patients with dry age-related macular degeneration (AMD)

BioCryst Pharmaceuticals, Inc. announced that it is offering to sell $55 million of its common stock in an underwritten public offering.

Total Revenues Increase 81% to $46.2 million Compared to $25.6 million in Prior-year Period

Approximately 90% of Patients Treated with INGREZZA in the Open-Label KINECT 4 Phase III Study Achieved a 50% or Greater Improvement in Their Tardive Dyskinesia Symptoms